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ABSTRACT
Purpose The blood brain barrier compromises glioblastoma
chemotherapy. However high blood concentrations of lipo-
philic, alkylating drugs result in brain uptake, but cause
myelosuppression. We hypothesised that nanoparticles could
achieve therapeutic brain concentrations without dose-
limiting myelosuppression.
Methods Mice were dosed with either intravenous lomustine
Molecular Envelope Technology (MET) nanoparticles
(13 mg kg−1) or ethanolic lomustine (6.5 mg kg−1) and tissues
analysed. Efficacy was assessed in an orthotopic U-87 MG glio-
blastoma model, following intravenous MET lomustine (daily
13 mg kg−1) or ethanolic lomustine (daily 1.2 mg kg−1 - the
highest repeated dose possible). Myelosuppression and MET
particle macrophage uptake were also investigated.
Results The MET formulation resulted in modest brain
targeting (brain/ bone AUC0-4h ratios for MET and ethanolic
lomustine = 0.90 and 0.53 respectively and brain/ liver
AUC0-4h ratios for MET and ethanolic lomustine=0.24 and
0.15 respectively). The MET formulation significantly in-
creased mice (U-87 MG tumours) survival times; with MET
lomustine, ethanolic lomustine and untreated mean survival
times of 33.2, 22.5 and 21.3 days respectively and there were
no material treatment-related differences in blood and femo-
ral cell counts. Macrophage uptake is slower for MET nano-
particles than for liposomes.
Conclusions Particulate drug formulations improved brain
tumour therapy without major bone marrow toxicity.
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ABBREVIATIONS
CLSM Confocal laser scanning microscopy
EDTA Ethylene diamine tetraacetic acid
GBM Glioblastoma multiforme
GCPQ N-palmitoyl-N-monomethyl-N-N-dimethyl-N,N,
N-trimethyl-6-O-glycol chitosan
HPLC High performance liquid chromatography
MeCN Acetonitrile
MET Molecular envelope technology
MRI Magnetic resonance imaging
TFA Trifluoroacetic acid
INTRODUCTION
Glioblastomamultiforme (GBM) is the most frequently occur-
ring primary brain tumour in adults (accounting for 65% of
primary brain tumours) and is the most aggressive, incurable
malignancy of the central nervous system (1). GBM continues
to be associated with poor prognosis, in spite of more recent
therapeutic advances, with less than a quarter of patients sur-
viving for 2 years after diagnosis (1–3). The median survival
time is 14 months and only a very small percentage (3–5%) of
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patients survive for more than 3 years (4). As for most cancers,
there is no actual cure for GBM.
GBM is characterized by uncontrolled cellular prolifera-
tion, diffuse infiltration and significant angiogenesis (5) and it
is initially diagnosed using magnetic resonance imaging
(MRI), although image interpretation is sometimes problem-
atic (6). Once diagnosed GBM is treated by surgical resection
followed by radiotherapy and chemotherapy, however, for
some tumours there is no acceptable treatment (7,8).
Chemotherapy, when indicated, is very challenging due to
the heterogeneous and infiltrating nature of tumours and ther-
apeutic agents being unable to access the tumour site; the
latter due to the blood brain barrier (5,9,10). Therefore,
methods to increase the localisation of chemotherapeutics to
the intracranial tumour site are needed. Nitrosoureas such as
carmustine and lomustine and other alkylating agents, e.g.
temozolomide have been employed in GBM chemotherapy,
however dose limiting toxicities, such as myelosuppression,
limit the effectiveness of these drugs (11–14).
It is thus clear that increasing the drug levels at the tumour site
while reducing drug levels in the bone marrow represent a sig-
nificant challenge for the chemotherapy of GBM. One way of
achieving high brain concentrations would be to increase the
blood concentration of the drug via a dose intensification regi-
men. In the case of a lipophilic drug, we hypothesise that nano-
particles may allow high drug concentrations to be administered
(dose intensification) such that high blood concentrations, and
thus high brain tumour levels, of these drugs are achieved, with-
out delivering high doses to the bone marrow. Dose intensifica-
tion has been attempted in patients but requires autologous pe-
ripheral blood stem cell (PBSC) support via PBSC infusions (15).
We have chosen to test this bone marrow avoidance
hypothesis with a class of nanoparticles which are
known to evade liver capture on intravenous injection
(16). These Molecular Envelope Technology (MET)
nanoparticles are constructed from N-palmitoyl-N-
monomethyl-N,N-dimethyl-N,N,N-trimethyl-6-O-glycol
chitosan, a self-assembling polymer amphiphile (17).
Drug loaded MET formulations were prepared and
their biodistribution and pharmacodynamics/ toxic ef-
fects studied. We sought to provide a mechanistic expla-
nation by also studying macrophage uptake of the MET
particles.
MATERIALS AND METHODS
Materials
All materials were obtained from Sigma Aldrich
Corporation, MO, USA, unless otherwise stated. All
solvents were obtained from Fisher Scientific, UK,
Loughborough, United Kingdom.
Cell Culture
U-87 MG human glioblastoma cell line was purchased from
American Type Culture Collection (ATCC® HTB-14™;
ATCC, Manassas, VA, USA). U-87 MG cells were grown in
Minimum Essential Medium (Life Technologies, Paisley, UK)
supplemented with FBS (10% v/v; Labtech International Ltd,
Uckfield, East Sussex, UK); sodium pyruvate (1 mM; Life
Technologies) and L-Glutamine (2 mM; Life Technologies).
Cells were maintained in culture (37°C in 5% CO2) for up to
14 days (splitting every 2–3 days when 75–80% confluence
was reached in the 75 cm2 tissue culture flask) before they
were used for tumour implantation.
Synthesis of the MET Polymer
The MET polymer was synthesised as previously described
(17). The characteristics of the MET polymer are shown in
Table I.
Preparation of MET Lomustine Nanoparticles
The nanoparticle formulation was prepared by probe sonicating
lomustine (2 mg ml−1), MET polymer (20 mg ml−1) soybean oil
(10mgml−1) and polysorbate 80 (5mgml−1) in dextrose solution
(5% w/v) on ice for 30 minutes (MSE Sonipreo 150, MSE UK,
with the instrument set at 50% of its maximum output). Each
time 26 ml of the MET formulation was prepared. The formu-
lation was filtered (0.22 μm) and the amount of lomustine encap-
sulated was measured by HPLC. To achieve high drug concen-
trations, the formulation from above (26 ml) was lyophilised and
reconstituted to 13 ml using double deionised water (Millipore
Water Purification System, EMDMillipore Corporation,Merck
KGaA, Darmstadt, Germany). Formulations were analysed by
HPLC using an analytical C18 derivatised silica gel based (Onyx
Monolithic: 5 μm; 100 x 4.6 mm; Phenomenex®, UK) column
using an Agilent (Agilent Technologies 1200 Series) HPLC
system.
Formulations were sized using a Malvern Nanosizer
(Malvern Instruments, Malvern, UK) at a temperature of
25°C and data analysed using the Contin method of analysis.
Formulations were imaged using transmission electron mi-
croscopy (TEM). For TEM imaging, a drop of the formula-
tion was placed on a formvar/carbon coated grid and excess
sample was blotted off on a filter paper (Whatman No 1). The
samples were then negatively stained (uranyl acetate 1% w/v)
and left for 1–2 minutes to air dry. Subsequently, images were
captured on the TEmicroscope using an AMT digital camera
(5 mega pixels; AMT Deben, UK Ltd).
The stability of the dried lomustine nanoparticles was stud-
ied over a 7-day period, with formulations stored at room
temperature and reconstituted periodically to produce a
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1 mg ml−1 lomustine formulation, the drug content analysed
and the particle size measured as described above.
Preparation of the Lomustine Ethanolic Formulation
The ethanolic lomustine formulation administered to male
CD-1 mice as control in the pharmacokinetic studies was pre-
pared as follows: 5 μl of polysorbate 80 was transferred into a
glass vial containing 2mg lomustine. The vial was vortexed for
1 minute and 895 μl of 5% w/v dextrose solution was added to
it. The vial was vortexed for another 1 minute. It was then
sonicated on ice for 30 minutes as described above. 100 μl of
10% v/v ethanol was added to the vial containing the
lomustine, polysorbate 80 and 5% w/v dextrose solution and
was vortexed for 1 minute. The content of the vial was filtered
through a 0.22 μm syringe filter (Millipore).
The ethanolic lomustine formulation administered as control
in the pharmacodynamics and toxicity studies was prepared by
vortexing lomustine (2 mg) in absolute ethanol (100 μl) with
polysorbate 80 (5 mg ml−1) in 5% w/v dextrose solution (final
ethanol concentration of 10% v/v). The resulting colloidal mix-
ture was then filtered (0.22μm;Millipore syringe filter) to remove
drug crystals and yield a non-particulate formulation.
The lomustine content of the formulations was determined
by HPLC analysis of the filtrate.
Animals
Ethics Statement
All animals were housed at the UCL School of Pharmacy’s
Biological Services Unit (BSU) and were acclimatized in the
BSU for 5–7 days before studies commenced. All animal stud-
ies were conducted in accordance with the policies and regu-
lations of the Home Office as stipulated in the Animals and
Scientific Acts 1986 UK, for the handling and care of labora-
tory animals used in scientific research, the recommendations
of the BSU and with the approval of the ethics committee.
Pharmacokinetics
The MET lomustine formulation (1.04 mg ml−1) was intrave-
nously administered to healthy male CD 1 mice (22–28 g) via
the tail vein at a dose 13mg kg−1 and in a dose volume of 289–
357 μl. Control animals were administered an ethanolic
lomustine formulation (0.37 mg ml−1) at a dose of
6.5 mg kg−1 and in a dose volume of 370–490 μl. Animals
were killed at various time points and the blood, brain, liver
and bone were sampled and the solid tissues stored at −80°C
until analyses could be performed on them. Plasma was ob-
tained by centrifugation of the blood samples (4000g, Hermle
Z 323K centrifuge, HERMLE Labortechnik GmbH
Siemensstr. 25 D-78564 Wehingen, Germany) at 4°C for
10 minutes and the plasma stored at −20°C until analyses
could be performed.
Tissue Analysis
To thawed plasma samples (0.2 ml) was added chilled
homogenising buffer [trizma HCl (50 mM), ethylene diamine
tetraacetic acid [(EDTA); (0.1 mM), pH=2, 0.2 ml], and
carmustine (20 μg ml−1; 0.1 ml) as internal standard. This
mixture was extracted with ethyl acetate (3 X 5 ml) and cen-
trifuged (1000g) for 10 minutes at 4 oC. The combined organ-
ic layers were evaporated to dryness under a stream of
nitrogen.
For analysis of brain, liver and bone samples, each tissue
was weighed and homogenised in homogenising buffer (1 ml)
and the homogeniser rinsings (2 X 1 ml) added to the homog-
enate. Carmustine (20 μg ml−1; 0.1 ml) was added to the
aqueous layer as an internal standard and the homogenate
extracted with ethyl acetate (3 X 10 ml). The mixture was
centrifuged (1000g) for 10 minutes at 4 oC and the combined
organic layers evaporated to dryness under a stream of nitro-
gen. The residues were subsequently reconstituted in mobile
phase [acetonitrile (MeCN; HPLC grade): 0.02% v/v
trifluoroacetic acid (TFA) in water (H2O): - 50: 50, 0.2 ml].
Table I MET Polymer
Characteristics Batch number Mole%
palmitoyl groups
Mole% quaternary
ammonium groups
Molecular weight
Mw (kDa) Mn (kDa) Polydispersity
GCPQOO28072009 26.2 11.1 * * *
GCPQOO18082009 26.6 6.2 * * *
GCPQOO28112009 22 8 * * *
GCPQSR11112011 21.9 12.4 8.4 7.8 1.1
GCPQFF18042012 23.7 13.2 9.5 8.6 1.1
GCPQFF20022013 19.1 13.5 9.3 7.8 1.2
GCPQFF26032013 23.4 14.4 10.2 6.5 1.6
*=The molecular weight of these polymers is in the region of 9–10 kDa from other studies (17,18)
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The reconstituted extracts were then subjected to HPLC
analysis.
Analysis for lomustine content in the tissue samples was
carried out using a gradient elution method with an initial
condition of 15% MeCN in TFA (0.02% v/v> in water) and
proceeding to 65% MeCN in TFA (0.02%v/v in water) over
10 minutes and at a flow rate of 2 mL min−1. The extracted
samples were injected (20 μl) over an onyx monolithic C18
(5 μm, 100 x 4.6 mm) Phenomenex® column set at 40°C.
Lomustine content was detected using a UV detector set at
230 nm. Calibration plot was done for plasma, brain, bone
marrow and liver from which the actual concentration of
lomustine in the samples was obtained. All results were
expressed as mean± standard deviation.
The pharmacokinetic parameters for the MET nanoparti-
cle lomustine formulation was obtained using the non-
compartmental method of the WinNonlin® software, version
4.1 (Pharsight Corporation, California 94040, USA).
Ex-Vivo Coherent Anti-Stokes Raman Spectroscopy
(CARS) Imaging
Deuterated N-palmitoyl-N-monomethyl-N-N-dimethyl-N,N,
N-trimethyl-6-O-glycol chitosan (MET) polymer was synthe-
sised as previously described (19) and deuterated MET parti-
cles prepared as previously described (19). Male CD-1 mice
(25–30 g) were intravenously dosed with deuterated MET
particles (10.4 mg ml−1) at a dose of 75 mg kg−1 and in a dose
volume of 200 μl. Animals were killed 1 hour after dosing.
The subsequently harvested brains were stored in neutral
buffered formalin (10% v/v). Fixed brains were cut into
0.5 mm thickness coronal slices with razor blades using a brain
matrix (Zivic instruments, Pittsburgh, PA, USA). Brain slices
were placed between two glass coverslips and sealed against
dehydration prior to imaging using CARS microscopy, as
previously described (20).
Bone Marrow Toxicity
Male CD-1mice were randomly assigned to treatment groups
and intravenously administered (via the tail vein) either MET
lomustine (2.02 mg ml−1) at a dose of 13 mg kg−1 in a dose
volume of≈200 μl or ethanolic lomustine (0.16 mg ml−1) at a
dose of 1.2 mg kg−1 in a dose volume of≈200 μl daily for 10
consecutive days.
Subsequently, mice were killed on 1, 7, 14, 21 or 30 days
after completion of the dosing and blood and femoral marrow
cell counts were assessed to determine the effect of the treat-
ments on the bone marrow.
Blood samples were obtained by cardiac puncture and
transferred into EDTA coated tubes (BD Microtainer® tube
with Dipotassium EDTA; Becton, Dickson and Company,
New Jersey, USA). Full blood counts were carried out using
an automatic haemocytometer (Sysmex Automated
Haematology Analyzer KX- 21, Sysmex Corporation,
Chuo-ku, Kobe 651-0073, Japan) to determine the levels of
the various blood components (white blood cells, red blood
cells and platelets). Femoral cells were obtained by flushing
out the bone marrow with 1 ml PBS and the cell counts were
determined by flow cytometry (MACSQuant Analyzer,
Miltenyi Biotec, GmbH, Germany).
Macrophage Nanoparticle Uptake
Nile Red Loaded MET Nanoparticles
MET Nile Red formulations for flow cytometry studies were
prepared by probe sonicating (QSonica sonicator,
Connecticut, USA) Nile Red (50 μg ml−1) and the MET poly-
mer (1 mg ml−1) in dextrose solution (5% w/v) on ice for
30 minutes, with the instrument set at 25% of its maximum
output. This was followed by centrifugation (1000g) for 30mi-
nutes at 4 oC to separate free Nile Red from encapsulatedNile
Red. The supernatant was then carefully collected immedi-
ately after centrifugation. MET Nile Red formulations for
confocal laser scanning microscopy (CLSM) experiments were
prepared by adding a solution of Nile Red (100 μg ml−1,
100 μL) in ethanol to a dispersion of the MET polymer
(1 mg ml−1) in dextrose solution (5% w/v), to a final volume
of 10 ml and probe sonicated on ice for 30 minutes, with the
instrument set to 25% of its maximum output. This was
followed by centrifugation (1000 g) for 30 minutes at 4oC to
separate free Nile Red from encapsulated Nile Red.
Nile Red Loaded Liposomes
Nile Red (50 μg ml−1), egg phosphatidyl choline (3 mg ml−1)
and cholesterol (1.4 mgml−1) were dissolved in chloroform (10
ml) and the resulting solution evaporated to dryness at 40°C
using a rotary evaporator. The thin lipid film obtained was
then hydrated with 5% w/v dextrose solution (5 ml) by shaking
for 30 minutes at room temperature to yield a homogenous
dispersion of egg phosphatidyl choline liposomes. This disper-
sion was subsequently probe sonicated on ice for 15 minutes,
as described above. The liposome formulation was then cen-
trifuged (1000g) for 30 minutes at 4 oC to eliminate free
unencapsulated Nile Red and the supernatant was carefully
collected immediately after centrifugation. These liposomes
were used for the flow cytometry studies.
Liposomal Nile Red formulations for CLSM imaging were
prepared by adding a Nile Red solution (100 μgml−1, 100 μL)
in chloroform to egg phosphatidyl choline (3 mg ml−1) and
cholesterol (1.4 mg ml−1) dissolved in chloroform (10 ml) and
following the methodology outlined above.
For both the Liposome and MET Nile Red formulations
used for CLSM, the concentration of Nile Red [determined
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by fluorimetry, λexc=488 nm and λem=655 nm, (LS – 50 B,
Perkin Elmer Inc., USA Spectrofluorimeter, with FLWinLab
(Perkin Elmer Inc, USA) software] was adjusted so that both
formulations had the same Nile Red concentrations (0.2 μg
ml−1) prior to application to the cells.
Cell Uptake Experiments
J774A.1 cells were cultured in Dulbecco’s Modified Eagle’s
Medium [(DMEM; ATCC® 30-2002™) modified to contain
L-glutamine (4 mM), glucose (4.5 g L−1), sodium pyruvate (1
mM), and 1500 mg L−1 sodium bicarbonate] supplemented
with 10% fetal bovine serum. The cells were maintained in
culture for at least 14 days before they were used for uptake
experiments. For flow cytometry and confocal imaging, cells
were handled according to methods described by Fernando
et al. 2010 (21) and Kim et al. 2012 (22) with some modifica-
tions, as outlined below.
Cells were seeded in 6 well plates at a density of 300,000
cells per well and incubated for 72 hours. Cells were then
treated with either MET Nile Red (0.3 μg ml−1) or the lipo-
some Nile Red (0.4 μg ml−1) formulations with some wells left
untreated as control. Cells were treated for predetermined
time periods of 5, 10, 30 minutes, 1 hour, 2 hours, or 4 hours.
Cells were then washed 3 times with cold Dulbecco’s phos-
phate buffered solution (DPBS, [calcium chloride anhydrous
(CaCl2; 0.9 mM), magnesium chloride (MgCl2.6H2O; 0.5
mM), potassium chloride (KCl; 2.7 mM, potassium phosphate
monobasic (KH2PO4; 1.5 mM), sodium chloride (NaCl 137.9
mM), sodium phosphate dibasic (Na2HPO4.7H2O; 8.1 mM),
pH 7.0–7.2] (2 ml / well) and then incubated in cold PBS –
EDTA (PBS- EDTA, [KH2PO4 (1.9mM), NaCl (138.9mM),
Na2HPO4.2H2O (6.6 mM), Titriplex III (EDTA Na2; 1.4
mM), lithium chloride (LiCl; 10.1 mM); pH 7.5)] (1 ml / well)
for 1–2 minutes. Cells were then harvested by gently scraping
and pipetting the cell suspension which was then centrifuged
and suspended in cold Ringers solution [Sodium chloride
(38.5 mM), Potassium chloride (1.4 nM), Calcium chloride
hexahydrate (0.5 mM), Sodium bicarbonate (0.6 mM); pH
7] and the nanoparticle uptake was quantified using the flow
cytometer (MACSQuant Analyzer, Miltenyi Biotec,
Germany) with uptake quantified with reference to the Nile
Red fluorescence. A total of 20,000 cells were measured in
each sample within the Nile Red positive channel. The exper-
iment was carried out in quadruplet for each formulation and
the untreated control cells.
For confocal microscopy imaging, cells were seeded in glass
bottom 35 mm tissue culture dishes (MatTek, Corporation,
Ashland, MA, USA) at a density of 75,000 cells per dish and
incubated for 48 hours. Cell uptake of the formulations was
then monitored in a time-lapse experiment set up on a Zeiss
LSM 710 laser scanning microscopy imaging unit (LASOS
Lasertechnik GmbH, Carl Zeiss, Franz-Loewen-Straße 2,
07745 Jena, Germany). Images were captured 3 minutes after
treatment with the formulation and subsequently after every
5minutes. The images were analysed using Zen 2009 software
(Carl Zeiss Microscopy GmbH Carl Zeiss Promenade 10,
07745 Jena, Germany).
Brain Tumour Studies
Brain Tumour Model and Magnetic Resonance Imaging
Tumour bearing mice brains were embedded in a mixture
(50: 50) of agarose gel (1% w/v) and formaldehyde solution
(4% w/v) prior to imaging, to fix the tissue and minimize
shifting of the samples during measurement. Images were col-
lected using a 1.5 T Philips Intera Gyroscan magnet (Philips
Healthcare, 5680 DA Best, The Netherlands). A high resolu-
tion T2-weighted Turbo Spin-Echo (TSE) sequence was used
(Repetition time (TR)=3000 ms, Echo time (TE)=110 ms,
flip angle=90 degrees, number of slices=54, voxel size=0.14
X 0.14 X 0.14 mm3, 10 averages). High-resolution images
were achieved by utilizing amicroscopy coil, diameter 23mm.
Image parameters were established in a preliminary exper-
iment, so as to optimize tumour edge detection. OSIRIX
software (Pixmeo SARL, Switzerland) was utilized to analyse
the MRI images and to measure the tumour volume, after a
manual determination of the edges in a slice-by-slice process.
Brain Tumour Treatment
Human glioblastoma (U-87 MG) cells were cultured in
Minimum Essential Medium (MEM) supplemented with foe-
tal bovine serum (FBS, 10% w/v); sodium pyruvate (1 mM; 5
ml) and L-Glutamine (1% w/v; 5 ml). Cells were maintained in
culture for up to 14 days before they were used for tumour
implantation.
Intracranial tumour models were established by orthotopic
implantation of the glioblastoma cells (100,000 cells) in the left
striatum (+0.5 mm anterior, – 2 mm lateral and to a depth of
3mm to the bregma, determined by a BENCHmark™ digital
stereotaxic control panel), of stereotactically fixed
anaesthetised (inhaled isoflurane) female CD-1 nude mice
(20–30g in weight). Once tumours were established (7 days
after implantation) mice were randomly assigned to treatment
groups and injected daily (tail vein) with the lomustine formu-
lations. Animals were either dosed with MET lomustine
(2.6 mg ml−1) at a dose of 13 mg kg−1 and a dose volume
of ≈ 200 μL or were dosed with ethanolic lomustine
(0.18 mg ml−1) at a dose of 1.2 mg kg−1 and a dose volume
of≈200 μL. Animals were dosed on 10 consecutive days and
the dose of the ethanolic lomustine formulation was the max-
imum dose volume that could be administered with repeat
dosing. Animals were weighed daily and animals were killed
once body weight had declined by 15% compared to the start
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of treatment. Examination of control animals once body
weight had reached this threshold value revealed tumours
which were 83.4 – 98.1 mm3 in volume, with a mean volume
of 91.8±7.57 mm3
Statistics
Data were subjected to a one-way analysis of variance
(ANOVA) with Tukey post hoc test using SPSS, version
17.0 software (SPSS Inc., Chicago, USA) for the
pharmacokinetics experiment and Minitab® 16 software
(Minitab, Inc., Pennsylvania, USA) for the brain tumour and
bone marrow toxicity experiments. The treatment groups
were compared two groups at a time for each time point
and the significance level was set at 0.05.
RESULTS
Synthesis of the MET Polymer
Nanomerics’MET is based on the self-assembling polymer N-
palmitoyl-N-monomethyl-N,N-dimethyl-N,N,N-trimethyl-6-
O-glycol chitosan, which assembles into nanoparticles in
aqueous media (17,18). Various batches of the MET polymer
were synthesised and characterised (Table I).
Preparation of MET Lomustine Nanoparticles
The nanoparticle formulations presented as translucent liq-
uids with a z-average mean
particle size of 336±0.44 nm and a polydispersity of 0.5.
The formulations were relatively polydisperse. Nanoparticles
were spherical, presumably consisting of lomustine filled oil
droplets in an oil in water formulation (Fig. 1) as well as
MET polymer and polysorbate 80 micelles. The oil droplets
were stabilised by the MET polymer and polysorbate 80. The
oil droplets/ micelles (it was not possibly to conclusively dis-
tinguish both particle types using electron microscopy) varied
in size from as little as 50 nm to up to 600 nm in size. Although
the majority of the oil droplets and micelles were below
100 nm in size, the PCS method of particle size analysis is
heavily weighted towards the larger sized particles. This is
the first report of Nanomerics’ MET acting as a stabiliser of
emulsion formulations and forming nanoemulsions.
The nanoemulsions were stable for up to 8 days when
stored dry at room temperature and could be reconstituted
into nanoemulsions (Fig. 2), with no sign of drug crystal for-
mation (data not shown).
Ex-Vivo CARS Imaging
CARS microscopy imaging detects clusters of polymer mole-
cules. The intensity of the CARS signal scales quadratically
Fig. 1 TEM image with negative staining of a lomustine formulation contain-
ing lomustine (2 mg ml−1), soya bean oil (10 mg ml−1), polysorbate 80
(5 mg ml−1), MET polymer batch GCPQOO28112009 [(mol %
palmitoylation=22 and mol % quaternisation=8%; 20 mg ml−1)] in dex-
trose (5% w/v). Formulations were prepared by reconstituting a freeze dried
sample containing 0.77 mg ml−1 lomustine to half its original volume.
Fig. 2 The stability of MET-lomustine nanoparticle formulations when stored
as the freeze dried cake at room temperature. Formulations were
reconstituted in water prior to analysis and no crystals were observed after
reconstitution.
1294 Fisusi et al.
with the concentration of bonds being probed within the focal
volume (23). Therefore, clusters of polymers in a single nano-
particle will generate significantly higher signal than individu-
al polymer molecules. The signal strength of the carbon-
deuterium CARS signal in Fig. 3 was several orders of mag-
nitude greater than the non-resonant background, and there-
fore was indicative of nanoparticles, rather than individual
polymer chains (24).
The deuterium labelled MET nanoparticles were
visualised in ex-vivo brain samples after intravenous injection
and were found to adhere to the brain endothelium, i.e. to the
luminal side of the blood brain barrier (BBB). TheMET poly-
mer CARS signal was not seen in the brain parenchyma and
as previously reported particles appear to adhere to the BBB
(20) and are not delivered to the brain (16). However, MET
nanoparticles are delivered to the BBB, adhere to the brain
endothelial cells (Fig. 3), from where they presumably release
loaded drug for transport across the BBB.
Pharmacokinetics
Following intravenous administration, plasma levels of
lomustine were relatively low with less than 1% of adminis-
tered dose detected in the plasma after 5 minutes (Fig. 4).
Lomustine is rapidly distributed to tissues and metabolised
and is not normally detected in the plasma (25).
The MET formulation improves the delivery of lomustine
to the brain by 2 fold by enabling a higher dose to be admin-
istered. Brain levels were similar to plasma levels for all for-
mulations, evidence of good across BBB transport for the drug
(Fig. 4, Tables II, III and IV). Additionally, when compared to
an ethanolic formulation of the drug at a dose of 6.5 mg kg−1,
the MET nanoparticles reduce the exposure (AUC0 – 4h) of
the bone (which includes the bone marrow) and liver to
lomustine by 25 and 38% respectively, whereas brain expo-
sure (AUC0 – 4h) for both formulations is similar (Fig. 4 and
Table II). The Cmax of the bone is also higher for the
6.5 mg kg−1 ethanolic formulation when compared to the
6.5mg kg−1MET formulation (Fig. 4d, Table IV). A doubling
of the lomustine dose by administering lomustine in the form
of the MET formulations (6.5mg kg−1 ethanolic lomustine
injection vs 13 mg kg−1 MET - lomustine) results in virtually
no change in the plasma AUC0-120, presumably because
lomustine is extensively distributed and metabolised in the
plasma (25), but does lead to a proportional increase in brain
AUC0-120 values (2.2 fold) and a limited increase in both bone
(1.2) and liver (1.3) AUC0-120 values (Tables II and III).
At the highest dose, MET lomustine delivers 0.33%
(0.77% per gram of brain) of the dose to the brain. It is clear
that the MET formulation produces higher brain levels, while
sparing the bone marrow and liver and this altered distribu-
tion is not underpinned by an increase in plasma exposure (as
is seen with other pharmaceutical particulates such as lipo-
somes (26,27)) but is due to differential tissue uptake
mechanisms.
Animals administered 6.5 mg kg−1 lomustine either as the
MET or ethanolic formulation showed no difference in the
drug’s plasma and brain Cmax, whereas the ethanolic formu-
lation produced a significantly higher Cmax in the bone (in-
cluding the bone marrow), when compared to the MET for-
mulation (Fig. 4, Table IV), we thus conclude that the MET
particles avoid the bone and bonemarrow. Furthermore, with
the 6.5 mg kg−1 dose, the MET particles are cleared faster
from the liver when compared to the drug injected as an
ethanolic solution (Fig. 4c) and we thus conclude that the
MET particles are not retained by the liver. Lomustine che-
motherapy is associated with dose limiting myelosuppression
(15,28–30) and hepatotoxicity in dogs (31). Myelosuppression
and hepatotoxicity are thus dose limiting adverse effects for
the drug and any formulation that minimises bone marrow
and liver exposure should have a positive impact on
treatment.
Bone Marrow Toxicity
Following the observation that the MET formulation deliv-
ered proportionately less lomustine to the bone and bone
marrow, an assessment of bone marrow toxicity was carried
out (Fig. 5) after chronic dosing of either MET lomustine
(13 mg kg−1) or an ethanolic formulation of lomustine at the
highest dose possible with multiple dosing (1.2 mg kg−1).
Full femoral cell counts (Fig. 5a) and white blood cell
counts (Fig. 5d) remained unchanged for both formulations.
There were minor changes in red cell count (83.0±8.0%
of control values) and haemoglobin levels (84.5±3.5% of
Fig. 3 Epi-detected CARS microscopy image illustrating the distribution of
deuterated MET nanoparticles within a mouse brain blood vessel, from a
sample harvested 1 hour after intravenous injection of deuterated MET nano-
particles (75 mg kg−1). The pump and Stokes wavelengths were tuned to
probe the C-D resonance at 2100 cm−1 (green contrast) and the C-H res-
onance at 2845 cm−1 (red contrast).
Lomustine Nanoparticles - A Strategy for Brain Cancer Treatments 1295
control values) with the high dose (13 mg kg−1) MET formu-
lation (Fig. 5b and e) on Day 1 with recovery after 7 days for
the red cell count and recovery after 30 days for the
haemoglobin levels. The changes in haemoglobin levels are
unlikely to be clinically significant as the range of acceptable
values for haemoglobin [male 14–18 g/dL; female 12–16
g/dL (32) spans at least a±20% range.
The main myelosuppressive changes were detected in the
platelet count, with platelet levels falling for both the low dose
ethanolic (1.2 mg kg−1) and high dose MET (13 mg kg−1)
formulation treated groups (Fig. 5c). The nadir values for both
groups were recorded on Day 7 with platelet nadir values of
56 and 79% of the control values recorded for the high dose
MET (13 mg kg−1) and low dose (1.2 mg kg−1) ethanolic
formulations respectively. For the ethanolic formulation treat-
ed animals, recovery was observed after 14 days while the
higher dose MET nanoparticle treated group showed recov-
ery after 21 days. In essence the administration of ten times the
ethanolic dose as a MET formulation resulted in very little
additional haematological toxicity when compared to the
low dose ethanolic formulation.
Macrophage Uptake
Macrophages are a heterogeneous group of cell types, which
are resident in a number of tissues, including the bonemarrow
and the liver; with one of their functions being the removal of
Fig. 4 The biodistribution of MET - lomustine nanomedicine formulations: a= plasma, b= brain, c= liver, d= bone (including bone marrow), ■ = MET –
lomustine (13 mg kg−1), □MET- lomustine (6.5 mg kg−1), ●= ethanolic lomustine (6.5 mg kg−1). The MET formulation improves the delivery of lomustine to
the brain by 2 fold by enabling a higher dose to be administered. Additionally, when compared to an ethanolic formulation of the drug at a dose of 6.5 mg kg−1,
the MET nanoparticles reduces the exposure (AUC0 – 4h) of the bone marrow and liver to lomustine by 25 and 38% respectively, *= significant difference
between the high dose MET formulation (13 mg kg−1) and all other formulations (p<0.05), #= significant difference between ethanolic formulation and both
MET formulations (p<0.05), §= significant difference between low dose MET formulation (6.5 mg kg−1) and all other formulations (p<0.05).
Table II Lomustine Tissue AUC0-120 Following Intravenous Dosing
Formulation and
dose
Dose Brain
AUC0-120min
(μg g−1 min)
Bone
AUC0-120min
(μg g−1 min)
Liver
AUC0-120min
(μg g−1 min)
BrainAUCo−120min
BoneAUCo−120min
BrainAUCo−120min
LiverAUCo−120min
MET - Lomustine 13 mg kg−1 44.06 49.03 187.18 0.899 0.235
Ethanolic lomustine 6.5 mg kg−1 21.54 40.89 141.10 0.527 0.152
MET - Lomustine 6.5 mg kg−1 17.28 30.79 87.64 0.561 0.197
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particulate cellular debris (33). In order to understand the
mechanisms underpinning the low liver, bone and bone mar-
row drug levels, we hypothesised that the main mechanism
could lie with a reduced uptake of the MET nanoparticles
by the macrophages in the liver and bone marrow.
Previously we have shown that on intravenous injection, liver
deposition is comparatively low for MET nanoparticles, with
only 4% of the intravenous dose found in the liver 10 minutes
after dosing (16), compared to peak levels of 67% of the intra-
venous dose of liposomes found in the liver 80 minutes after
dosing (34). We hypothesised that the low liver uptake of
MET nanoparticles could be due to the low uptake by liver
macrophages and it is conceivable that the bone levels may
also be reduced due to low bone marrowmacrophage uptake.
In vitro within the J774A.1 cell line, the uptake of liposomal
Nile Red is rapid with 89% of cells positive for Nile Red within
10minutes of incubation (Fig. 6a).WhileMETnanoparticles are
also taken up by macrophages, uptake is significantly slower with
71% of cells positive for MET Nile Red one hour after incuba-
tion. Uptake as opposed to a simple cell surface association was
verified by confocal laser scanning microscopy, which shows the
Nile Red signal at the level of the nucleus (Fig. 6b and c).
The rate of macrophage uptake is thus slower for theMET
nanoparticles when compared to the uptake by liposomes and
it is thus possible that the reduced liver and bone and bone
marrow drug levels and consequent relatively mild effect on
the bone marrow of the dosage form could be the result of
reduced macrophage uptake. The macrophage uptake data
thus provides further proof that the MET nanoparticles
appear not to be taken up by the reticuloendothelial system
to an appreciable extent.
Brain Tumour Model
U-87 MG intracranial tumours were successfully established
and imaged by MRI (Fig. 7).
Brain Tumour Treatment
Animals with established tumours (7 days after implantation of
the U-87 MG cells) were treated for 10 consecutive days, with
treatment commencing on Day 7 and concluding on Day 16.
The mean survival time for animals that received the MET
lomustine (13 mg kg−1 per day) formulation was 33.17 days,
while untreated control animals had a mean survival time of
21.33 days (Fig. 8a II). A comparable mean survival time
(31 days) was obtained for the MET lomustine formulation
treated animals in a previous (first) study. The untreated con-
trol animals in the first study had a mean survival time of
17.14 days (Fig. 8a I). Animals that received the ethanolic
lomustine (1.2 mg kg−1) formulation of the drug had similar
mean survival times of 22 and 22.5 days in the first and second
studies respectively (Fig. 8a I and II). The dose of lomustine
(1.2 mg kg−1) administered in the ethanolic formulation was
limited by the poor aqueous solubility of lomustine and was
the dose achievable with multiple dosing when lomustine was
formulated in 10% v/v ethanol containing polysorbate 80
(5 mg ml−1).
During treatment the animals’ body weight was monitored
and there was no significant difference between the body
weights when all groups were compared (untreated, ethanolic
and MET treated animals – Fig. 8b). This indicates that the
high dose formulation did not cause gross toxicities and the
MET formulation thus enabled the administration of a higher
dose, with the lack of uptake by the bone marrow and liver
likely to limit the toxic effects (15,28–30) that are normally
observed with lomustine therapies.
MRI analysis showed that tumour volumes for the MET
lomustine formulation treated animals in the first study were
significantly (p<0.05) lower than those for the ethanolic for-
mulation treated animals (Fig. 9a). However, there was an
Table III Lomustine Plasma AUC0-120 Following Intravenous Dosing
Formulation MET - Lomustine Ethanolic
lomustine
MET - Lomustine
Dose 13 mg kg−1 6.5 mg kg−1 6.5 mg kg−1
Plasma AUC0-120
(μg ml−1 min)
48.35 48.21 48.33
BrainAUCo−120min
PlasmaAUCo−120min
0.91 0.45 0.36
LiverAUCo−120min
PlasmaAUCo−120min
3.87 2.93 1.81
BoneAUCo−120min
PlasmaAUCo−120min
1.01 0.848 0.637
Table IV Lomustine Cmax Values
Formulation Dose (mg kg−1) Plasma (μg ml−1) mean± s.d Brain (μg g−1) mean± s.d Liver (μg g−1) mean± s.d Bone (μg g−1) mean± s.d
MET lomustine 13 1.84±0.43* 2.74±0.67* 9.85±1.32* 1.82±0.31
Ethanolic lomustine 6.5 0.84±0.32 1.24±0.40 3.00±1.33 1.46±0.15
MET lomustine 6.5 0.70±0.15 0.76±0.27 2.12±0.98 0.78±0.34*
*= significant differences between formulation and all other formulations (p<0.05)
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outlier with a tumour volume considerably larger than the
others within the group of animals that had received the
ethanolic formulation. This necessitated the conduct of the
second experiment to confirm the findings from the first study.
Analysis of the tumour volumes in the second experiment
confirmed that tumour volumes for animals that received
the MET lomustine formulation were generally lower than
those of animals that received the ethanolic formulation and
untreated control animals (Fig. 9b). However, the differences
were not statistically significant (p>0.05).
DISCUSSION
The MET formulation presented as a nanoemulsion in which
the oil droplets are presumably coated with theMET polymer
and polysorbate 80 (Fig. 1). The size distribution is heteroge-
neous and comprises micelles as well as oil droplets. The
distribution of the two amphiphiles—the MET polymer and
polysorbate 80 between the micelles and the oil droplets is
unknown. This formulation enables a higher dose to be ad-
ministered as a bolus and this is in turn associated with a
longer survival time (Fig. 8a), when compared to the admin-
istration of the lomustine ethanolic—polysorbate 80 formula-
tion at the maximum bolus dose possible. However, it is the
relatively reduced delivery of drug to the liver and bone
(Fig. 4, Tables II and III) and the resultant minimal effect of
the high dose formulation on myelosuppression (Fig. 5) that is
the most interesting feature of the MET formulation.
Lomustine chemotherapy is associated with dose limiting
myelosuppression (15,28–30) and autologous stem cell rescue
(15). Hepatotoxicity in dogs is also a feature of lomustine che-
motherapy (31). Myelosuppression and hepatotoxicity are
thus dose limiting adverse effects for lomustine and any for-
mulation that minimises bone marrow and liver exposure
would have a positive impact on treatment and allow patients
Fig. 5 Mice blood cell counts and haemoglobin assessments following 10 daily doses of lomustine formulations: white bar=control animals, grey bar=ethanolic
lomustine formulation (1.2 mg kg−1), black bars=MET lomustine (13 mg kg−1), *= statistically significantly different from all formulations, §= statistically
significantly different from control animals (untreated).
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to take fewer treatment breaks, as the tumour would presum-
ably continue to grow during such treatment breaks allowing
the supporting microenvironment to recover rapidly.
Lomustine is normally given orally and we administered it
intravenously in this study, using it as a model drug to test
the bone marrow sparing potential of the intravenous MET
formulation.
We have found that MET nanoparticles are taken up at a
slower rate in vitro by mouse monocyte derived macrophage
cell lines (Fig. 6) and while these are not tissue resident
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Fig. 6 (a) The uptake of Nile red
loaded particles in the J774A.1 cell
line (a macrophage cell line). Cells
were treated with Nile red loaded
MET nanoparticles or Nile red
loaded liposomes at a Nile red
concentration of 0.3 μg ml−1 and
0.4 μg ml−1 respectively. The cells
were washed to remove excess
formulation prior to analysis. (b):
Confocal laser scanning microscopy
image of J774A.1 cells following
incubation with MET Nile Red
particles (0.2 μg ml−1) for
18 minutes. (c) Confocal laser
scanning microscopy image of
J774A.1 cells following incubation
with liposomal Nile Red (0.2 μg ml-
1) for 18 minutes. Scale
bar=10 μm.
Fig. 7 Magnetic resonance T2
weighted images of an established
intracranial tumour.
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macrophages which have distinct functions, such as immune
surveillance, removal of cell debris and iron processing (33), it
is clear that these macrophages phagocytose liposomes more
readily than when compared to the MET nanoparticles and
we conclude that the surface chemistry of the MET particles
must be responsible for their slower phagocytosis when com-
pared to liposomes. Such a conclusion is not without prece-
dent as the exposure of phosphatidyl serine on the surface of
apoptotic cells enables these cells to be taken up by tissue
resident macrophages expressing the phosphatidyl serine re-
ceptor (33).
It is possible that this reduced macrophage uptake is a key
driver for the low bone and liver levels of the drug (Fig. 4). Low
liver uptake of MET nanoparticles has been demonstrated in a
number of studies (16,35). For example the coating of peptide
nanofibres with the MET polymer resulted in a significant re-
duction in liver deposition (35), hence evidence is beginning to
emerge in support of the hypothesis that the MET polymer
coating diverts nanoparticles from the liver (Fig. 4), spleen (16)
and bone marrow (Fig. 4) on intravenous injection. While it is
clear that there are correlations between macrophage uptake
(Fig. 6) and liver (Fig. 4) and spleen (16) deposition of MET
nanoparticles, when compared to liposomes (34) (Fig. 6), we
have not proven that the reducedmacrophage uptake observed
actually leads to reduced liver, spleen and bone marrow depo-
sition ofMET nanoparticles on intravenous injection, especially
as tissue resident macrophages (which are proliferative and of
embryonic origin) (33) were not used in our in vitro studies.
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Fig. 8 (a) I (top- first study) and II (bottom- second study): Survival plots of female CD-1 mice bearing an intracranial U-87MG tumour, following treatment with:
a) MET lomustine (13mg kg−1 per day 2.6mgml−1, dose volume=≈ 200 μL, black filled symbols), b) ethanolic lomustine (1.2 mg kg−1 per day; 0.18mgml−1,
dose volume=≈ 200 μL, grey filled symbols) or c) untreated (unfilled symbols). Mice were killed once body weight had declined by 15% compared to the start of
treatment. Mice were administered 10 doses with treatment commencing on Day 7 and treatment concluded on Day 16. (b) (I and II): Body weight monitoring
of female CD-1 mice bearing intracranial U-87 MG tumours following treatment with lomustine formulations: filled black symbols=MET lomustine (13 mg kg−1
per day, 2.6 mg mL−1, dose volume=≈ 200 μL, filled grey symbols=ethanolic lomustine (1.2 mg kg−1 per day, 0.18 mg mL−1, dose volume=≈ 200 μL),
unfilled symbols=untreated control animals. Body weights were not significantly different during the treatment phase of the experiment.
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To further understand the advantages offered by the liver/
bone sparing MET formulation, which in essence targets the
drug to the brain, one must consider the fact that dose inten-
sification would allow the drug to overwhelm the enzyme
repair systems that confer resistance to the therapeutic, such
as the enzyme O6-methylguanine-DNA methyltransferase
(MGMT), a DNA repair enzyme (7). Dose intensification,
when tried in the clinic, although beneficial, is usually con-
founded by the toxicity of the regimen, most notably haema-
tological toxicities (36). In our studies, dose intensification with
the MET formulation does not confer significant additional
myelosuppressive effects when compared to the low dose
ethanolic formulation and yet is therapeutically beneficial in
this mouse intracranial tumour model. Dose intensification
with the MET system definitely warrants clinical testing.
Dose intensification with chemotherapy may be achieved
either by increasing the dose or by increasing the frequency of
dosing. The resulting haematological toxicities will take the
form of neutropenia, thrombocytopenia or a reduction in
red blood cells (36,37). Neutropenia, may lead to fatal infec-
tions and is the most frequently occurring toxic effect encoun-
tered with cytotoxic drugs (37). Due to the short life span (6–
14 hours) (38) of granulocytes, they are usually the first to be
negatively affected during chemotherapy (38). However, in
the current study, the white blood cells were not affected by
the high dose MET formulation and neither were the total
bone marrow cells (Fig. 5a and d). Platelets with a life span of
9–10 days in humans (39) and 4–5 days in the mouse (40) are
usually the next susceptible cell type to be affected by chemo-
therapy after the granulocytes (41). The results of the current
study are consistent with this platelet vulnerability, as all treat-
ment groups show a significant drop in platelet counts after
7 days, although platelets counts did revert to baseline levels
after 14 and 21 days for the low dose ethanolic (1.2 mg kg−1)
and high dose MET (13 mg kg−1) formulations, respectively
(Fig. 5c).
Toxic effects on the red blood cells are the last to be seen
due to the longer life span of the erythrocytes with a life span
of 100–120 days in humans (41,42) and 30–52 days in the
mouse (40) and although there were minor drops recorded
in the red cell counts and haemoglobin levels in our studies,
these changes in red blood cell counts and haemoglobin levels
amount to no more than a 20% change and thus are unlikely
to be clinically significant.
CONCLUSION
Our findings show that lomustine dose intensification with the
MET particle system improved the survival of intracranial
tumour bearing mice and did not produce significant addi-
tional myelosuppressive effects as bone and bone marrow de-
position of the drug was reduced with the MET system. Liver
deposition was also reduced with the MET system and since
myelosuppression and liver toxicity are features of lomustine
therapy, such a dose intensification strategy warrants clinical
testing.
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Fig. 9 (a) (top- first study) and (b) (bottom- second study): Tumour volumes
for female CD-1 mice bearing intracranial U-87 MG tumours following treat-
ment with lomustine formulations. QLOM=MET lomustine (13 mg kg−1
per day, 2.6 mg mL−1, dose volume=≈ 200 μL, LOM-ETOH=ethanolic
lomustine (1.2 mg kg−1 per day, 0.18 mg mL−1, dose volume=≈ 200 μL),
CONTROL=untreated control animals. * = Significantly different fromMET
lomustine (13 mg kg−1) formulation treated animals.
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